Verrica Pharmaceuticals Inc
VRCA
View Detailed Chart
7.820USD
-0.290-3.58%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
74.21MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-3.58%
5 Days
-1.26%
1 Month
+85.75%
6 Months
+33.72%
Year to Date
+11.71%
1 Year
+12.65%
View Detailed Chart
TradingKey Stock Score of Verrica Pharmaceuticals Inc
Currency: USD Updated: 2025-12-19Key Insights
Verrica Pharmaceuticals Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 83/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 16.33.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Verrica Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
6
analysts
Buy
Current Rating
16.333
Target Price
+101.40%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Verrica Pharmaceuticals Inc Highlights
StrengthsRisks
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).
Growing
The company is in a growing phase, with the latest annual income totaling USD 7.57M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 7.57M.
Undervalued
The company’s latest PE is -2.74, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 2.46M shares, decreasing 37.23% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 225.21K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.95.
Verrica Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Verrica Pharmaceuticals Inc Info
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).
Ticker SymbolVRCA
CompanyVerrica Pharmaceuticals Inc
CEORieger (Jayson)
Websitehttps://verrica.com/
FAQs
What is the current price of Verrica Pharmaceuticals Inc (VRCA)?
The current price of Verrica Pharmaceuticals Inc (VRCA) is 7.820.
What is the symbol of Verrica Pharmaceuticals Inc?
The ticker symbol of Verrica Pharmaceuticals Inc is VRCA.
What is the 52-week high of Verrica Pharmaceuticals Inc?
The 52-week high of Verrica Pharmaceuticals Inc is 9.821.
What is the 52-week low of Verrica Pharmaceuticals Inc?
The 52-week low of Verrica Pharmaceuticals Inc is 3.280.
What is the market capitalization of Verrica Pharmaceuticals Inc?
The market capitalization of Verrica Pharmaceuticals Inc is 74.21M.
What is the net income of Verrica Pharmaceuticals Inc?
The net income of Verrica Pharmaceuticals Inc is -76.58M.
Is Verrica Pharmaceuticals Inc (VRCA) currently rated as Buy, Hold, or Sell?
According to analysts, Verrica Pharmaceuticals Inc (VRCA) has an overall rating of Buy, with a price target of 16.333.
What is the Earnings Per Share (EPS TTM) of Verrica Pharmaceuticals Inc (VRCA)?
The Earnings Per Share (EPS TTM) of Verrica Pharmaceuticals Inc (VRCA) is -2.858.
Related Instruments
+1.32%
-0.88%
+1.75%
+0.83%
+0.60%
+0.38%
+0.91%
+1.03%
+2.32%
+0.60%
+0.40%
+1.97%
+1.63%
+1.21%
+0.65%
+0.66%
+2.57%
0.00%
-0.44%
+1.06%Popular Symbols
